GLORIA MESHBERG: Open Payments
NPI 1437629938 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$476 in 20 payments from 6 companies in 2025. Trend: 2023 $459 · 2024 $314 · 2025 $476
Food & beverage: $476
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 10 | $192 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $110 |
| Mirum Pharmaceuticals, Inc. | 2 | $85 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Madrigal Pharmaceuticals | 1 | $32 |
| ORPHALAN INC | 1 | $22 |
Products named: XIFAXAN, Livmarli, TERLIVAZ, REZDIFFRA, CUVRIOR.
Industry payments across NY — which companies pay providers there.
